The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
An 18-year-old is using a high-dose hair loss treatment with 40mg daily dutasteride, finasteride, minoxidil, tretinoin, and topical bicalutamide. Despite health risk concerns, especially liver issues, they report hair regrowth progress and intend to continue the regimen.
A 28-year-old shared surprising hair regrowth progress after 20 days using topical minoxidil, micro needling, GHK-cu, and BPC-157 injections. The user noted a significant reduction in their bald spot and overall hair improvement.
Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. User asks about Redensyl's effectiveness, questioning if it's another ineffective remedy.
A user shared 14-month progress pictures using topical finasteride and minoxidil for hair loss. Others commented on the impressive results and asked about age, improvement timeline, and how to obtain finasteride.
A 28-year-old male using only oral finasteride 1mg since May 15, 2024, reports no side effects and significant hair improvement. He plans to continue finasteride for three more months and is considering adding D3+K2 drops, zinc, folate, and magnesium glycinate.
Hair is growing faster after 2 weeks of using topical vitamin D3 in alcohol/oil. The user plans to continue the experiment for 3 months before giving a full review.
The conversation discusses a hair loss treatment regimen involving minoxidil, finasteride, RU58841, JXL069, and nizoral shampoo. The user reports seeing new black dots in areas where hair hasn't grown in years, suggesting potential regrowth.
The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.
Breezula may be released around 2027 but its effectiveness for advanced thinning is uncertain, and it might be expensive. Users discuss alternatives like low-dose topical finasteride and combining it with Breezula for better results.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
User reported hair regrowth and thicker hair after using rosemary oil, zinc, biotin, vitamin D, and a better diet. They believe rosemary oil contributed the most to the improvement.
The conversation discusses using scalp massage, balms like Ethera and L'Occitane, and dietary changes such as rosemary tea and tofu to address hair loss. The user is also considering high-intensity interval training and slow breathing to improve hair regrowth.
PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.
New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.
A 17-year-old user reports significant hair regrowth using 1mg finasteride daily and 5% minoxidil once daily. Other users discuss the effectiveness and age considerations of finasteride.
A user's 3-month progress with a combination of finasteride, minoxidil and dermarolling for hair loss; other users shared their experiences and advice.
A user is experiencing androgenic alopecia and is considering using Vichy's aminexil for hair regrowth. They seek advice on its effectiveness and whether to combine it with microneedling.
The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.
The user is experiencing hair regrowth using oral minoxidil, finasteride, dermastamping, and ketoconazole shampoo. Suggestions include adding pyrilutamide or considering dutasteride instead of finasteride.
A 23-year-old male shared his 4-month progress using 1mg finasteride daily, along with B-12 and D3+K2 supplements, to address hair loss. He sought feedback on using generic finasteride and shared his journey to regain confidence.
Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.
Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.
A potential new hair loss treatment, HMI-115, and the possibility of discontinuing finasteride in favor of it. The conversation also includes discussion about other benefits of using finasteride.
A 14-month update on a FUE hair transplant, and the effects of male pattern baldness. People discussed products such as Minoxidil, finasteride, Kerastase Chronologiste shampoo and care oil, and RU58841 to help treat hair loss.
A 26-year-old male has been using Redensyl for nearly two months without progress and recently switched to minoxidil. He is also taking multivitamins with biotin and using ciclopirox shampoo for dandruff.
A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.
The conversation discusses Scube3, a seemingly new and obscure treatment for hair loss, with limited information available and a link to a patient intake form.